As previously reported the Supreme Court of Canada will hear an appeal of the Federal Court of Appeal decision affirming a trial decision invalidating AstraZeneca’s patent relating to esomeprazole (NEXIUM) for lack of utility. The hearing is scheduled for November 8, 2016.